Find clinical trials for Lung Cancer in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lung Cancer trials near Hanyang, Seoul, KOR:
to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...
Phase 2
Seoul, Korea, Republic of and 95 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Seoul, Korea, Republic of and 83 other locations
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Seoul, Gangnam-gu, Korea, Republic of and 59 other locations
and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...
Phase 2
Seoul, Korea, Republic of and 47 other locations
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....
Phase 1
Seoul, Korea, Republic of and 14 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Seongnam Si, Gyeonggi Do, Korea, Republic of and 51 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Seoul, Korea, Republic of and 209 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Seoul, Korea, Republic of and 57 other locations
Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...
Phase 1
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 42 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...
Phase 1
Seoul, Korea, Republic of and 38 other locations
Clinical trials
Research sites
Resources
Legal